

ICTHIC.COM



12th INTERNATIONAL CONFERENCE ON THROMBOSIS AND HEMOSTASIS ISSUES IN CANCER

MAY 17-19, 2024

**Monumental Complex of "Sant'Agostino"
University of Bergamo, Italy**

PROGRAM

AUSPICES

The meeting is held under the auspices of:



Società Italiana
di Ematologia
(SIE)



In collaboration with:



CONFERENCE ORGANIZATION

Conference Chairmen

Anna Falanga, MD

University Milan Bicocca,
Hospital Papa Giovanni XXIII Bergamo;
Italy

Benjamin Brenner, MD

Rambam Health Care Campus,
Technion-Israel Institute of Technology,
Haifa; Israel

Alok A. Khorana, MD, FACP

Taussig Cancer Institute, Cleveland
Clinic, Cleveland OH; USA

Chairman Emeritus

Frederick R. Rickles, MD, FACP

The George Washington University, Katzen Cancer Center,
Medical Faculty Associates
Washington; USA

Steering Committee

Benjamin Brenner
Haifa; Israel

Andrea Remuzzi
Bergamo; Italy

Anna Falanga
Bergamo; Italy

Caterina Rizzi
Bergamo; Italy

Alok A. Khorana
Cleveland, OH; USA

Laura Russo
Bergamo; Italy

Co-organized by

Fondazione ARTET Onlus (fondazioneartet.it)



Scientific Secretariat

Anna Falanga, Laura Russo, Marina Marchetti
Alfonso Vignoli, Chiara Ambaglio, Luca Barcella
Hospital Papa Giovanni XXIII Bergamo; Italy

Organizing Secretariat

Servizi C.E.C. Srl Via Daste e Spalenga 15 - 24125 Bergamo, Italy
Phone +39.366.7541661 - info@icthic.com


PROGRAM OVERVIEW

MAP

| Friday May 17 th | Saturday May 18 th | Sunday May 19 th |
|---|--|--|
| 07:30 Secretariat opening | 07:30 Secretariat opening | 07:30 Secretariat opening |
| 10:00 Congress opening | 09:00 Plenary session 3 Anticoagulation in hematological cancer patients Aula Magna | 08:30 Plenary session 5 Past, present, and future of CAT - A round table discussion Aula Magna |
| 10:15 Plenary session 1 Emerging trends in cancer-associated thrombosis (Part I) Aula Magna | 10:50 Coffee break | 10:15 Plenary session 6 Novel biomarkers for predicting clinical outcomes in cancer patients Aula Magna |
| 12:30 Debate Do we need more complex and specific RAMs for CAT? Aula Magna | 11:15 Plenary session 4 Exploring the relationship between hemostasis and cancer: new insights Aula Magna | 12:05 Lunch |
| 13:30 Lunch | 13:30 Lunch Symposium see page 30 Aula Castoldi | 13:05 Plenary session 7 Anticoagulation in cancer patients Aula Magna |
| 14:30 Coffee | 14:30 Coffee | 15:00 Concluding remarks |
| 15:00 Plenary session 2 Emerging trends in cancer-associated thrombosis (Part II) Aula Magna | 15:00 Poster discussion sessions see pages 15-24 Aula Magna Rooms 6-7-8 | |
| 17:15 Tea break | 17:00 Interactive session Spotlight on prevention of VTE in cancer patients Aula Magna | |
| 17:45 Plenary Lecture 8 th Simon Karparkin Memorial Lecture Aula Magna | 18:15 Special "Noble" session Aula Magna | |
| 18:45 | 19:00 | |
| | 20:30 Social Dinner | |

LEGEND

- Congress opening
- Plenary session 1-7
- Debate
- Plenary Lecture
- Lunch Symposium
- Poster discussion sessions
- Interactive session
- Special "Noble" session
- Concluding remarks




FACULTY

| | |
|--------------------------------|--|
| Ageno Walter - Switzerland | Marchetti Marina - Italy |
| Agnelli Giancarlo - Italy | Maugeri Norma - Italy |
| Barca-Hernando María - Spain | Muñoz Martín Andrés J. - Spain |
| Becattini Cecilia - Italy | Napolitano Mariasanta - Italy |
| Bertoletti Laurent - France | Noble Simon - UK |
| Brenner Benjamin - Israel | O’Sullivan Jamie M. - Ireland |
| Cali Bianca - Switzerland | Pabinger Ingrid - Austria |
| Carpenedo Monica - Italy | Panicot-Dubois Laurence - France |
| Castaman Giancarlo - Italy | Patell Rushad - USA |
| Cazzaniga Marina Elena - Italy | Prandoni Paolo - Italy |
| De Candia Erica - Italy | Rak Janusz - Canada |
| Dentali Francesco - Italy | Raskob Gary E. - USA |
| Di Nisio Marcello - Italy | Reinhardt Christoph - Germany |
| Falanga Anna - Italy | Remuzzi Andrea - Italy |
| Graf Claudine - Germany | Rizzi Caterina - Italy |
| Grandone Elvira - Italy | Rossi Elena - Italy |
| Gresele Paolo - Italy | Sanfilippo Kirsten - USA |
| Kakkar Ajay K. - UK | Santi Roberto M. - Italy |
| Kenet Gili - Israel | Schieppati Francesca - Italy |
| Khorana Alok A. - USA | Shlush Liran I. - Israel |
| Kuderer Nicole - USA | Siegal Deborah - Canada |
| Labianca Roberto - Italy | Simioni Paolo - Italy |
| Lee Agnes Y.Y. - Canada | Stanworth Simon J. - UK |
| Li Ang - USA | Taraboletti Giulia - Italy |
| Lyman Gary H. - USA | ten Cate-Hoek Arina J. - The Netherlands |
| Mandalà Mario - Italy | ten Cate Hugo - The Netherlands |
| Mantha Simon - USA | Zwicker Jeffrey - USA |

SCIENTIFIC PROGRAM

Friday, May 17th
Aula Magna

| | | |
|---------------|---|-------|
| 10:00 -10:15 | Congress opening Opening remarks from the Conference Chairmen Anna Falanga, Benjamin Brenner, Alok A. Khorana | |
| 10:15 - 12:30 | PLENARY SESSION 1 Emerging trends in cancer-associated thrombosis (Part I) Chairs: Benjamin Brenner (Israel), Paolo Simioni (Italy) | |
| 10:20 – 10:45 | Endothelial cell dysfunction in cancer: a modulator of CAT and metastasis? Jamie M. O’Sullivan (Ireland) | PL-01 |
| 10:45 - 11:10 | Artificial intelligence in CAT Rushad Patell (USA) | PL-02 |
| 11:10 - 11:35 | The gut microbiome in cancer and thrombosis Christoph Reinhardt (Germany) | PL-03 |
| 11:35 - 12:00 | Stroke in patients with cancer Deborah Siegal (Canada) | PL-04 |
| 12:00 – 12:15 | Selected Abstracts Immune checkpoint blockade promotes thrombosis via T-cell and neutrophil activation, and tumor-cell associated tissue factor (TF) in a murine model of colorectal cancer Y. Shim, B. Sharma, Y. Hisada, N. Mackman, J. Palumbo, M. Diaz-Montero, A.A. Khorana, <u>K. McCrae</u> (USA) | OC-01 |
| 12:15 – 12:30 | Navigating the interplay of cancer, hemostasis, and thrombosis: investigating tissue factor in colorectal cancer (CALGB/SWOG 80405) <u>S. Algaze</u> , Y. Yang, J. Millstein, F. Battaglin, S. Soni, P. Mittal, K. Ashouri, A. Wong, P. Jayachandran, H. Arai, J.H. Lo, W. Zhang, L. Torres-Gonzalez, H. Liebman, H.J. Lenz (USA) | OC-02 |



SCIENTIFIC PROGRAM

SCIENTIFIC PROGRAM

| | | |
|---------------|---|-------|
| 12:30 -13:30 | DEBATE Do we need more complex and specific RAMs for CAT? Chairs: Paolo Prandoni (Italy), Mario Mandalà (Italy) YES: Andrés Jesús Muñoz Martín (Spain) NO: Ingrid Pabinger (Austria) | |
| 13:30 – 15:00 | Lunch & Coffee | |
| 15:00 – 17:15 | PLENARY SESSION 2 Emerging trends in cancer-associated thrombosis (Part II) Chairs: Laurent Bertoletti (France), Francesco Dentali (Italy) | |
| 15:05 – 15:30 | Trends and updates on the epidemiology of cancer-associated thrombosis Ang Li (USA) | PL-05 |
| 15:30 – 15:55 | Cancer immunotherapy in CAT Claudine Graf (Germany) | PL-06 |
| 15:55 – 16:20 | Bleeding and thrombosis during CAR-T therapy Elena Rossi (Italy) | PL-07 |
| 16:20 – 16:45 | Location of metastasis and complications of anticoagulant treatment María Barca-Hernando (Spain) | PL-08 |
| 16:45 – 17:00 | Selected Abstracts Prediction of clinically significant bleeding in patients anticoagulated for cancer-associated venous thromboembolism: validation of the B-CAT score in a cohort of patients from the Teseo study J. López Robles, M. Sánchez Cánovas, C. Iglesias, L. Ortega Morán, L. Sánchez Togneri, J. Rubio, I. Fernández Pérez, M. García De Herreros, I. García Escobar, R. Porta, E. Brozos, M. Carmona Campos, E. Martínez De Castro, H. Olivares, T. Quintanar, S. García Adrián, M. Covela Rúa, A. Carmona Bayonas, P. Jiménez Fonseca, A.J. Muñoz Martín On behalf of Teseo Registry Investigators (Spain) | OC-03 |

| | | |
|---------------|---|-------|
| 17:00 – 17:15 | Tissue factor pathway-related biomarkers in pancreatic cancer: plasma levels of activated factor VII-antithrombin complex may predict venous thromboembolism E. Campello, M. Spizzo, A. Castagna, F.T.M. Bosch, F.I. Mulder, N. Van Es, S. Gavasso, P. Pattini, A. Rousseau, P. Van Dreden, S. Friso, H.R. Büller, P. Simioni, N. Martinelli (Italy, The Netherlands, France) | OC-04 |
| 17:15 – 17:45 | Tea break | |
| 17:45 – 18:45 | PLENARY LECTURE 8th Simon Karparkin Memorial Lecture Chairs: Anna Falanga (Italy), Benjamin Brenner (Israel), Alok A. Khorana (USA) Introduction to Lecture Alok A. Khorana (USA) VTE treatment in patients with cancer: reflections on an evolving landscape Agnes Y.Y. Lee (Canada) | |

Saturday, May 18th

Aula Magna

| | | |
|---------------|---|-------|
| 9:00 – 10:50 | PLENARY SESSION 3 Anticoagulation in hematological cancer patients Chairs: Roberto Santi (Italy), Giancarlo Castaman (Italy) | |
| 9:05 – 9:30 | VTE and mortality in patients with hematological malignancies Kristen Sanfilippo (USA) | PL-09 |
| 9:30 – 9:55 | Management of CAT in thrombocytopenia: the uncertain balance between risks and benefits of platelet transfusion to support anticoagulation Simon J. Stanworth (UK) | PL-10 |
| 9:55 – 10:20 | Pharmacological approach to increase platelet count: from ITP to chemotherapy-induced thrombocytopenia Monica Carpenedo (Italy) | PL-11 |
| 10:20 – 10:35 | Selected Abstracts The risk of thromboembolic recurrence outweighs the risk of major bleeding in cancer patients treated with tinzaparin, even in patients with fragility criteria. Meta-analysis of prospective studies involving 1413 individual patients’ data L. Mahé, C. Chapelle, G. Poenou, L. Jara-Palomares, A.Y.Y. Lee, O. Sanchez, G. Meyer, P. Girard, S. Laporte (France, Spain, Canada) | OC-05 |
| 10:35 – 10:50 | Rapid exclusion of clinically relevant plasma levels of direct oral anticoagulants in patients using the DOAC dipstick in various indications J. Harenberg, W. Ageno, C. Becattini, J. Douxfils, A. Falanga, S. Hetjens, M. Marchetti, J. Vassart, F. Violi, C. Weiss, J. Weitz On Behalf of The Doac Poct Working Group (Germany, Switzerland, Italy, Belgium, Canada) | OC-06 |
| 10:50 – 11:15 | Coffee break | |

| | | |
|---------------|--|---------------------------------------|
| 11:15 – 13:30 | PLENARY SESSION 4 Exploring the relationship between hemostasis and cancer: new insights Chairs: Erica De Candia (Italy), Hugo ten Cate (The Netherlands) | |
| 11:20 – 11:45 | Platelets: a weapon against cancer Paolo Gresele (Italy) | PL-12 |
| 11:45 – 12:10 | FXa inhibitors in cancer progression Bianca Calì (Switzerland) | PL-13 |
| 12:10 – 12:35 | Coagulome and tumor microenvironment Janusz Rak (Canada) | PL-14 |
| 12:35 – 13:00 | Crosstalk between NETs and tumor progression Laurence Panicot-Dubois (France) | PL-15 |
| 13:00 – 13:15 | Selected Abstracts Investigating a proposed anti-cancer immunity effect of rivaroxaban in breast cancer U. Singh, J. Castle, S. Pritchard, R. Hunt, J.R. Harvey, C. Holcombe, A. Volleamere, B. Hogan, R. Vinayagam, P.G. Roy, M. Bramley, J. Kokan, C. Palmieri, K. Cox, J. Thachil, R. Jackson, A. Marshall, L. Turner, N.J. Bundred, C.C. Kirwan (UK) | OC-07 |
| 13:15 – 13:30 | Tumor platelet transcriptome changes affected by micrometastasis C. Dinis Santos Rodrigues, J. Braun, S. Schubert, F. Marini, C. Graf, B. Schrörs, W. Ruf (Germany, USA) | OC-08 |
| 13:30 – 14:30 | Lunch Symposium (see page 30) | |
| 14:30 – 15:00 | Coffee | |
| 15:00 – 16:00 | POSTER DISCUSSION SESSIONS I-IV Poster session I: Biomarkers/Hypercoagulability I Chair: Norma Maugeri (Italy) Poster session II: Thrombohemorrhagic complications Chair: Elena Rossi (Italy) | (see pages 15-19) Room 7 Room 6 |

SCIENTIFIC PROGRAM

Poster session III: Epidemiology Room 8
Chair: Marina Marchetti (Italy)

Poster session IV: Thromboprophylaxis in cancer Aula Magna
Chair: Arina J. ten Cate-Hoek (The Netherlands)

16:00 – 17:00 **POSTER DISCUSSION SESSIONS V-VIII** (see pages 20-24)

Poster session V: Treatment of thrombosis in cancer Aula Magna
Chair: Elvira Grandone (Italy)

Poster session VI: Hemostatic proteins and cancer biology Room 6
Chair: Giulia Taraboletti (Italy)

Poster session VII: Therapeutic challenges Room 8
Chair: Mariasanta Napolitano (Italy)

Poster session VIII: Biomarkers/Hypercoagulability II Room 7
Chair: Francesca Schieppati (Italy)

17:00 – 18:15 **INTERACTIVE SESSION**

Spotlight on prevention of VTE in cancer patients
Chair: Ajay K. Kakkar (UK)

A case of thrombosis in medical inpatient
Walter Ageno (Switzerland)

A case of thrombosis in surgical patient
Giancarlo Agnelli (Italy)

A case of thrombosis during anti-cancer drug treatment
Marina Elena Cazzaniga (Italy)

Discussants: Anna Falanga (Italy), Gary H. Lyman (USA)

18:15 – 19:00 **SPECIAL “NOBLE” SESSION**

Chairs: Anna Falanga (Italy), Caterina Rizzi (Italy)

Patient and public involvement in CAT research: necessary or glorified tokenism?
Simon Noble (UK)

SCIENTIFIC PROGRAM

Sunday, May 19th
Aula Magna

8:30 – 10:15

PLENARY SESSION 5

Past, present and future of CAT - A round table discussion
Chairs: Elvira Grandone (Italy), Alok A. Khorana (USA)

8:35 – 9:00

New drugs, old problems: immune checkpoint inhibitors and CAT PL-16
Alok A. Khorana (USA)

9:00 – 9:25

Real-world outcomes data for DOAC vs LMWH vs other anticoagulants: promises and pitfalls PL-17
Nicole Kuderer (USA)

9:25 – 9:50

FXI inhibitors: a new option for the prevention and treatment of cancer-associated thrombosis PL-18
Marcello Di Nisio (Italy)

General Discussion

10:15 – 12:05

PLENARY SESSION 6

Novel biomarkers for predicting clinical outcomes in cancer patients
Chairs: Marina Marchetti (Italy), Andrea Remuzzi (Italy)

10:20 – 10:45

Proteomics prediction of CAT and mechanistic insights PL-19
Jeffrey Zwicker (USA)

10:45 – 11:10

Age-related clonal hemopoiesis and thrombosis PL-20
Liran I. Shlush (Israel)

11:10 – 11:35

Machine learning for the prediction of CAT PL-21
Simon Mantha (USA)

11:35 – 11:50

Selected Abstracts
Growth differentiation Factor-15 is associated with risk of major bleeding in cancer patients without anticoagulation: results from a prospective cohort study OC-09
C. Englisch, S. Nopp, I. Pabinger, F. Moik, D. Steiner, A.M. Starzer, M. Fritzer-Szekeres, M. Preusser, A. Berghoff, C. Ay (Austria)

SCIENTIFIC PROGRAM

POSTER DISCUSSION SESSIONS

Saturday 18th

| | | |
|---------------|---|-------|
| 11:50 – 12:05 | Predictive value of activated FXI-antithrombin complex in cancer associated thrombosis (CAT): a prospective cohort study in lung cancer patients <i>P. Gomez-Rosas, M. Marchetti, M. Nagy, H.M.H. Spronk, L. Russo, C. Verzeroli, S. Gamba, C.J. Tartari, S. Bolognini, C. Ticozzi, F. Schieppati, R. Sarmiento, F. De Braud, G. Masci, C. Tondini, F. Petrelli, F. Giuliani, A. D’Alessio, A. Santoro, G. Gasparini, R. Labianca, H. ten Cate, A. Falanga</i> <i>On behalf of The Hypercan Investigators (Italy, The Netherlands)</i> | OC-10 |
| 12:05 – 13:05 | Lunch | |
| 13:05 – 14:55 | PLENARY SESSION 7 Anticoagulation in cancer patients <i>Chairs: Anna Falanga (Italy), Roberto Labianca (Italy)</i> | |
| 13:10 – 13:35 | Risk of recurrent VTE in cancer patients after discontinuation of anticoagulant therapy <i>Gary E. Raskob (USA)</i> | PL-22 |
| 13:35 – 14:00 | Extended antithrombotic prophylaxis after cancer surgery <i>Cecilia Becattini (Italy)</i> | PL-23 |
| 14:00 – 14:25 | Trends in the management of pediatric and adolescent patients with cancer-associated VTE <i>Gili Kenet (Israel)</i> | PL-24 |
| 14:25 – 14:40 | Managing a cancer-associated thrombosis clinic - opportunities and challenges <i>S. Gilani, D. Chandra (UK)</i> | OC-11 |
| 14:40 – 14:55 | Prognostic factors associated with recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism: systematic review and meta-analysis <i>F. Khan, T. Tritschler, C. Marx, V. Lanting, B. Rochweg, A. Tran, S. Fernando, D. Lorenzetti, H. Wunsch, J. Holodinsky, K. Fiest, Ht. Stelfox, A. Delluc, D. Fergusson, G. Le Gal, P. Wells, N. Van Es, J.M. Connors, M. Carrier (Canada, Switzerland, The Netherlands, USA)</i> | OC-12 |
| 15:00 | Concluding remarks <i>Anna Falanga, Benjamin Brenner, Alok A. Khorana</i> | |

15:00 – 16:00

Poster session I

Room 7

Biomarkers/Hypercoagulability I

Chair: Norma Maugeri (Italy)

| | |
|-------|--|
| PO-01 | Altered whole blood thrombin generation and hyperresponsive platelets associate with thromboembolic events in patients with pancreatic ductal adenocarcinoma <i>R.A.L. Willems, J. Konings, D. Huskens, H. ten Cate, J. De Vos-Geelen, B. De Laat, M. Roest</i> |
| PO-02 | Thrombo-hemorrhagic events and tissue factor expression in newly diagnosed patients with acute promyelocytic leukemia receiving induction therapy <i>F. Schieppati, L. Russo, C.J. Tartari, T. Barbui, E. Di Bona, M. Marchetti, A. Falanga</i> |
| PO-03 | Plasma markers of hemostatic activation and fibrinolysis in patients with non-metastatic castration-resistant prostate cancer before and after secondary hormonal therapy and anti-PSMA radioimmunotherapy <i>Z. Davidson, C. Thomas, D.M. Nanus, A. Patel, N. Adra, Y. Zakharia, J. Osborne, N.H. Bander, S.T. Tagawa</i> |
| PO-04 | Altered plasmin generation in patients with pancreatic ductal adenocarcinoma <i>R. Willems, I. De Simone, C. Biesmans, J. Konings, S. Tufaha, H. ten Cate, B. De Laat, M. Roest, D. Huskens, J. De Vos-Geelen</i> |
| PO-05 | An MRI radiomics approach to predict the hypercoagulable status of gliomas <i>Z. Saidak, A. Laville, S. Soudet, M.A. Sevestre, J. M. Constans, A. Galmiche</i> |
| PO-06 | Antiphospholipid antibodies in women with endometrial and cervical cancer <i>J. Khizroeva, A. Makatsariya, V. Bitsadze, A. Solopova, A. Vorobev, I. Elalamy, M. Tretyakova, N. Makatsariya, T. Mashkova, Z. Aslanova, E. Kudryavtseva, I. Dikaeva, E. Efendieva</i> |
| PO-07 | Rapid and effective isolation of human platelets from whole blood: maximizing purity for evaluating proteomics methods in clinical studies for cancer patients <i>V. Markhus, D. Goplen, F. Selheim</i> |
| PO-08 | Factor VIII: C improves prediction of VTE by the thrombogyn score <i>E. Ibrahim, M.P. Ward, C. Mc Goldrick, D. Ramesh, S. O’ Toole, F. Abu Saadeh, L.A. Norris</i> |

POSTER DISCUSSION SESSIONS

15:00 – 16:00

Poster session II

Room 6

Thrombohemorrhagic complications

Chair: Elena Rossi (Italy)

- PO-09 Association between anticoagulation-related bleeding and mortality in patients with hematological malignancies and cancer-associated venous thromboembolism**
T.-F. Wang, S. Luo, M. Schoen, A. Afzal, S. Chang, K. Carson, K. Sanfilippo
- PO-10 Association between anticoagulation-related bleeding and mortality in persons with solid tumors**
A. Mahmoud, S. Luo, M. Schoen, B. Gage, A. Afzal, S. Chang, K. Carson, K. Sanfilippo
- PO-11 Cancer-associated venous thromboembolism: a case of a possible resistance to DOAC**
S. Kozhukhov, N. Dovganych
- PO-12 Risk of rethrombosis and major bleeding in women with cancer included in the TESEO-SEOM registry**
S. García Adrián, L. Ortega Morán, A. Carmona-Bayonas, C. Iglesias Pérez, E.M. Brozos Vázquez, E. Martínez De Castro, C. Díaz Pedroche, F. Nería, T. Quintanar Verduguez, M. Covela Rúa, P. Jiménez Fonseca, M. Sánchez Cánovas, J.A. Santiago Crespo, M. Biosca Gómez De Tejada, F.J. Pelegrin Mateo, B. Obispo Portero, M. Lobo De Mena, A.J. Muñoz Martín
On Behalf of Teseo Registry Investigators
- PO-13 Risk of car t-cell therapy-related thrombosis and bleeding: preliminary results of the multicenter ‘follow that car’ registry**
A.K. Ko, P.N.J. Mutsaers, F.W.G. Leebeek, M.N. Lauw
- PO-14 Estimating risk of bleeding and thrombosis for thrombocytopenia in cancer-associated splanchnic vein thrombosis: a time-varying analysis**
K. Barnum, M. Andersen, M. Fernandez, L. Dodge, C. Hsu, J. Berry, J. Zwicker, R. Patell
- PO-15 Thrombotic thrombocytopenic purpura associated with nivolumab and ipilimumab immunotherapy in metastatic melanoma: a case report**
J. Depaus, E. Collinge, A. Sonet
- PO-16 Further proof that the Ottawa Score fails to predict recurrent VTE in cancer patients. Meta-analysis of individual patient data**
C. Chapelle, I. Mahé, G. Poenou, L. Jara-Palomares, A.Y.Y. Lee, O. Sanchez, G. Meyer, P. Girard, S. Laporte

POSTER DISCUSSION SESSIONS

15:00 – 16:00

Poster session III

Room 8

Epidemiology

Chair: Marina Marchetti (Italy)

- PO-17 Usual-site venous thromboembolism in patients with cancer-associated splanchnic vein thrombosis**
K. Barnum, M. Andersen, M. Fernandez, L. Dodge, C. Hsu, J. Berry, J. Zwicker, R. Patell
- PO-18 Deep vein thrombosis as an initial symptom of prostate cancer: a case report**
M. Shorova, N. Jovanova, B. Panev, M. Stoileva, R. Grubovik-Ratsvorcev, E. Petkovik, D. Stambolieva
- PO-19 Prognostic value of hull score 0 versus subsegmental unsuspected pulmonary embolism in cancer patients: a comparative analysis**
F. Haque, J. Ryde, L. Broughton, A. Stephens, A. Pillai, S. Mirza, V. Brown, G. Averya, G. Bozas, A. Maraveyas
- PO-20 Venous thromboembolism and risk of cancer in patients with stroke: a population-based cohort study**
O. Rosenkrantz, D. Nagy, E. Horváth-Puhó, C.H. Fuglsang, H.T. Sørensen
- PO-21 Venous thromboembolism and risk of cancer in patients with a history of migraine: a population-based cohort study**
O. Rosenkrantz, D. Nagy, E. Horváth-Puhó, C.H. Fuglsang, H.T. Sørensen
- PO-22 Sensitivity and positive predictive value of cancer-associated venous thromboembolism diagnoses in the Danish national patient register**
T.F. Overvad, M.T. Severinsen, S.P. Johnsen, S.S. Madsen, K. Kannik, L.G. Stenfeldt, T.B. Larsen, P.B. Nielsen
- PO-23 Venous thromboembolism in cancer patients and self-rated health: a cross-sectional study**
J. Viuff, S. Korsgaard, C. Nielsen, F. Kristensen, H.T. Sørensen
- PO-24 Poly (ADP-ribose) polymerase inhibitors (PARPI) – associated thrombosis in patients with ovarian cancer: a study of the Spanish Society of Medical Oncology (SEOM) thrombosis and cancer group**
J. López Robles, M. Sánchez Cánovas, F.J. García Verdejo, D. Cacho Lavin, C. Díaz Pedroche, A. Garrido Fernández, E. Coma Salvans, T. Quintanar, C. Salvador Coloma, D. Fernández Garay, J.D. Cumplido, A.I. Ferrer Pérez, A. Carbó Bagué, J. Teigell, A.J. Muñoz Martín

POSTER DISCUSSION SESSIONS

PO-25 Impact of thromboembolic events across the span of breast cancer survivorship: data from a large observational study on long-term breast cancer survivors

J. Illarramendi, J.I. Arraras, G. Asin, A. Manterola, E. Salgado, S. De La Cruz, E. Gomez, M.V. Aznar, J. Coll, M.J. Paloma, M. Rodriguez-Calvillo, J.J. Illarramendi, M. Redondo

PO-26 Venous thromboembolism and risk of cancer in patients with atopic dermatitis

H.T. Sørensen, C.H.F. Nielsen, D. Nagy, E. Horváth-Puhó

PO-27 Epidemiologic study of patients with thrombotic events referred to a tertiary hospital in southern Iran

A. Akbari, S. Haghpanah, H. Barzegar, A. Shahsavani, A. Afrasiabi, S. Parand, M. Karimi

PO-28 Rates of venous thromboembolism during neoadjuvant chemotherapy for ovarian cancer: a national study of UK Gynaecological Cancer Centres

S. Oxley, M. Sideris, M. Brincat, A. Pandya, G. Owens, N. Gomes, V. Braden, A. Durden, N. Ryan, K. Baxter, J. Prince, N. Zamesa, S. Bryan, S. Tanna, F. Kokka, J. Waters, J. Lowe Zinola, A. McCormick, B. Johnston, C. Nott, S. Ahmed, D. Blake, J. Dilley, S. Dobbs, M. Lockley, A. Olaitan, M. Thomas

POSTER DISCUSSION SESSIONS

15:00 – 16:00

Poster session IV

Aula Magna

Thromboprophylaxis in cancer

Chair: Arina J. ten Cate-Hoek (The Netherlands)

PO-29 Electronic health record (EHR) integration of thromboembolism risk stratification model in patients with cancer

A. Li, D. Guffey, R. Bandy, S. Ma, O. Jafari, E. Zhou, M. Ranjan, K. Martin, A. Jotwani

PO-30 Apixaban thromboprophylaxis in multiple myeloma (MM) patients receiving chemotherapy: a cohort study

Y. Tan, S. Mariathasan, Z. Sayar, J. Sive, A. Tailor, M. Thomas

PO-31 Tinzaparin prophylaxis in patients with metastatic colorectal cancer (Protincol)

A.J. Muñoz Martín, J. De La Camara, I. García Escobar, R.C. Álvarez Llosa, P. Gonzalez Villarroel, D. Fernández Garay, M. Pampols, M. Guillot, F.J. Pelegrín Mateo, E. Jiménez, J. Sastre, E. Martínez De Castro, E. Coma, L. París Bouzas, A.I. Ferrer Pérez, Y. De Miguel, E. Mompradé Olivé, L. Robles Díaz, J.M. Soria, M. Salgado

PO-32 Comparative analysis of risk prediction scores including all type of cancer associated thrombosis

I. González, B. Lobato, M. Ruiz, I. Ávila, M. Salgado, V. Pachón, J. Martinez, E. Martinez, A. Ferrer, J. Rubio, I. Garcia, I. Fernandez, T. Quintanar, C. Font, J. Soto, L. Ortega, J.M. Soria, A.J. Muñoz Martin

PO-33 Direct oral anticoagulants for the prevention of venous thromboembolism after cancer surgery: a systematic review and network meta-analysis

G. N. Pititto, G. Maraziti, A. Squizzato, A. Fiaccadori, C. Becattini

PO-34 Barriers to VTE prevention in ambulatory oncology practice: a clinician-based survey

M. Ranjan, A. Jotwani, A. Li, K. Martin

PO-35 Exploring the impact of KRAS mutation type on the thrombotic risk

M. Seladas, R. Escaleira, J. Mendes, J. Gramaça, I. Guerreiro

PO-36 Antithrombotic and anti-leukenic effects of ricinus communis in benzene-induced leukemic wistar rats

A. Kosamat, A. Olabisi, I. Ajayi

PO-37 Cancer associated thrombosis (CAT): optimizing VTE prevention and improving patient care experience

N. Khargie, S. Jenkins, E. Yeo, N. Miscevic, M. Dzyuba, C. Kurtin

PO-38 Cancer associated thrombosis: surveying patients' awareness and education needs

I. Tataka, A. Li, A. Parks, J. Schaefer, A. Gutierrez Bernal, S. Chaturvedi, A. Mahajan, J. May, L. Tefera, B. Roberston, L. Lake, D. Angelini, R. Patell

POSTER DISCUSSION SESSIONS

16:00 – 17:00

Poster session V

Aula Magna

Treatment of thrombosis in cancer

Chair: Elvira Grandone (Italy)

- PO-39 Use of tinzaparin in the treatment of PICC-related thrombosis in cancer patients**
[I. De La Haba](#), E. Coma, C. Tudela, A. Benito, R. Arcega, M. Merino, E. Colomé
- PO-40 Direct oral anticoagulants are associated with lower circulating levels of procoagulant extracellular vesicles compared to low molecular weight heparin treatment in patients with cancer associated thrombosis**
[H. Macleod](#), N. Coptý, D. Doherty, R. Power, N. Ryan, K. Saeed, E. O'Rourke, S. Macleod, R. Faryal, L. Weiss, S. Kelliher, B. Kevane, F. Ní Áinle, P. Maguire
- PO-41 Antithrombotic therapy decision-making in advanced cancer: key facilitators and barriers**
[A.A. Højen](#), E. Baddeley, M. Edwards, S. Sivell, K. Lifford, C. Font, V. M. Arfuch, N. Coma-Auli, I. Mahé, H. Enggaard, M. Sogaard, F.A. Klok, S. Noble
- PO-42 Effects of tinzaparin on the presence of residual thrombus in patients with cancer-associated thrombosis**
C. Rosa-Linares, M. Barca-Hernando, S. Lopez Ruz, V. Garcia-Garcia, [L. Jara-Palomares](#)
- PO-43 A single-center experience with the use of tinzaparin for the treatment of venous thromboembolic events in breast cancer patients on therapy with targeted drug agents**
[J. Illarramendi](#), J.I. Arraras, L. Teijeira, E. Salgado, S. De La Cruz, E. Gómez, M.V. Aznar, J. Coll, M. Martínez-Calvillo, M.J. Paloma, M. Redondo, J.J. Illarramendi
- PO-44 Treatment of cancer associated venous thrombosis with Edoxaban in patients receiving concomitant Enzalutamide**
T. Groves, [N. Pease](#), S. Noble, L. Green, R. Ali Khan
- PO-45 Chemotherapy associated cerebral venous sinus thrombosis (CVST)-experience from a tertiary cancer centre**
[S. Sawant](#), A. Daddi, G. Goel
- PO-46 Duration of anticoagulation in cancer associated thrombosis what is ideal**
T.S. Hund, Y.R. Tan, [N. Pandit](#)

POSTER DISCUSSION SESSIONS

16:00 – 17:00

Poster session VI

Room 6

Hemostatic proteins and cancer biology

Chair: Giulia Taraboletti (Italy)

- PO-47 What is the ideal anticoagulant?**
K. Karthigayan, Z. Qi, [N. Pandit](#)
- PO-48 A 44 kilos uterine fibroid resection complicated by extended venous thromboembolism not solved by full dose Edoxaban. A clinical case**
[A.M. Fioretti](#), T. Leopizzi, D. La Forgia, R. De Luca, D. Oreste, S. Strippoli, P. Pizzutolo, P. Scicchitano, G. Cormio, N.D. Brunetti, C.G. Tocchetti, S. Oliva
- PO-49 Anti-proliferative, anti-angiogenic and anti-invasive effect of antithrombin in glioblastoma multiforme**
[J. Peñas-Martínez](#), D. Zaragoza-Huesca, S. Espín, C. Martínez, R. González-Conejero, M.L. Lozano, V. Vicente, I. Martínez
- PO-50 Rivaroxaban compared to no treatment in early breast cancer patients (the tip trial, Eudract 2014-004909-33): effect on EPCAM serum concentrations as a surrogate for circulating tumour cells (CTCS)**
[J. Castle](#), S. Pritchard, R. Hunt, J.R. Harvey, C. Holcombe, A. Volleamere, B. Hogan, R. Vinayagam, P.G. Roy, M. Bramley, J. Kokan, C. Palmieri, K. Cox, J. Thachil, R. Jackson, A. Marshall, L. Turner, N.J. Bundred, C.C. Kirwan
- PO-51 Characterisation of procoagulant fibroblasts in the early breast cancer microenvironment through ex vivo culture**
H. Ogunlayi, [J. Castle](#), R. Clarke, S. Pritchard, S. Wahballa, Y.Y. Lim, C.C. Kirwan
- PO-52 Cancer associated thrombosis alters neutrophils to promote pancreatic ductal adenocarcinoma progression**
A. Thomas, Y. Li, K. Kalikasingh, E. Tong, D. Prots, A. Madera, S. Lapping, [L. Nayak](#)
- PO-53 Glucocorticoids as transcriptional regulators of the tumor coagulome of oral squamous cell carcinomas**
[F. Racine](#), C. Louandre, C. Godin, B. Chatelain, Z. Saidak, A. Galmiche
- PO-54 Description of clinical and molecular features in cancer-associated venous thromboembolism**
[M. Roca-Herrera](#), S. Serradell, B. Alonso, S. Eremiev, A. De Torner, P. Martínez, P.P. Mascaró, J. Yaringaño, P. Benito, O. Mirallas, J. Hernando

POSTER DISCUSSION SESSIONS

PO-55 MIR5683 predicts venous thromboembolism in advanced gastric cancer through regulation of fibrinolysis and endothelial TFPI expression

D. Zaragoza Huesca, J. Peñas Martínez, R. Teruel, G. Ricote, A. Carmona Bayonas, A. Fernández Montes, P. Jiménez Fonseca, L. Macia Rivas, P. Morales Del Burgo, L. Visa, R. Hernández, E. Martínez De Castro, A. Pereira Elorrieta, M.E. De La Morena Barrio, P. Garrido Rodríguez, M.L. Lozano, C. Martínez, R. González Conejero, I. Martínez Martínez

PO-56 AAV-mouse DNase I sustains long-term DNase I expression in vivo and suppresses breast cancer metastasis

M. Herre, K. Vemuri, J. Cedervall, S. Nissl, F. Saupe, J. Micallef, H. Lindman, C.A. Maguire, G. Tetz, V. Tetz, A.K. Olsson

16:00 – 17:00

Poster session VII

Room 8

Therapeutic challenges

Chair: Mariasanta Napolitano (Italy)

PO-57 Performance of established VTE risk assessment models for the prediction of all-cause mortality in patients with cancer – results from a prospective cohort study

N. Vladoic, C. Englisch, J. Berger, F. Moik, A. Berghoff, M. Preusser, I. Pabinger, C. Ay

PO-58 Prediction of coronary heart disease risk in blood or marrow transplant survivors - a BMT survivor study (BMTSS) report

R. Gangaraju, Q. Meng, L. Hageman, W. Landier, N. Balas, E. Ross, L. Francisco, A. Bosworth, F. Lennie Wong, D. Weisdorf, R. Bhatia, S. Forman, S. Armenian, S. Bhatia

PO-59 Patients' experiences, values and perspectives on antithrombotic therapy (ATT) decision-making in advanced cancer

A.A. Højen, E. Baddeley, M. Edwards, S. Sivell, K. Lifford, C. Font, V.M. Arfuch, N. Coma-Auli, I. Mahé, H. Enggaard, M. Sogaard, F.A. Klok, S. Noble

PO-60 Clinicians' views and experiences of antithrombotic therapy decision making in advanced cancer

A.A. Højen, E. Baddeley, M. Edwards, S. Sivell, K. Lifford, C. Font, V.M. Arfuch, N. Coma-Auli, I. Mahé, H. Enggaard, M. Sogaard, F.A. Klok, S. Noble

PO-61 Long term venous thromboembolic complications in cancer patients with COVID-19 infection

M. Blancarte Ibarra, A. Morales Arteaga, L. Phan, E. Young, C. Rojas Hernandez

PO-62 Catheter-related thrombosis vs fibroblastic sleeve. Incidence and impact in oncological and hematological patients with peripherally inserted central catheter

M. Nunziata, F.P. Damiano, F. Cannavacciuolo, M. Amitrano, S. Mangiacapra

POSTER DISCUSSION SESSIONS

PO-63 Hemostasis and thrombosis consultations at a cancer dedicated institution: a six-month experience

C. Rothschild, A.G.S. Brandão, E. Okazaki, V. Rocha, P.R. Villaga

PO-64 Patterns of venous thromboembolic events and their clinical implications in patients with neuroendocrine neoplasms

M. Roca, S. Serradell, S. Eremiev, B. Alonso, A. García, A. Casteras, P. Martínez, A. De Torner, J. Capdevila, J. Hernando

PO-65 Cancer-associated thromboembolism (CAT) risk factors as well as frailty predict immunotherapy-associated venous thromboembolism (IAT) in patients with non-small cell lung cancer (NSCLC)

M.A. Cheong, K. Sanfilippo, D.C. Calverley, N. Kuderer

16:00 – 17:00

Poster session VIII

Room 7

Biomarkers/Hypercoagulability II

Chair: Francesca Schieppati (Italy)

PO-66 Plasma kininogen levels predict development of venous thrombosis in cancer patients: analysis of samples from the Cassini Study

A.A. Khorana, E. Feener, Y. Shim, D. Lee, J. Barnard, K. McCrae

PO-67 Erythrocyte-related parameters in relation to cancer diagnosis: a case-cohort study of healthy subjects

C.J. Tartari, S. Bolognini, C. Ticozzi, S. Gamba, L. Russo, C. Verzeroli, C. Giaccherini, L. Barcella, M. Marchetti, A. Falanga

PO-68 Nets biomarkers in women with endometrial and cervical cancer

A. Makatsariya, J. Khizroeva, V. Bitsadze, A. Solopova, A. Vorobev, N. Makatsariya, I. Elalamy, J-C. Gris, M. Tretyakova, E. Slukhanchuk, K. Grigoreva, Z. Aslanova, E. Kudryavtseva, M. Malykh-Bakhtina, A. Lazarchuk

PO-69 Markers of coagulopathy in multiple myeloma

K. Chasakova, L. Slavik, D. Starostka, J. Ulehlova, T. Papajik, J. Minarik

PO-70 Thrombus characteristics (composition and response to in vitro thrombolysis) and plasma biomarkers in cancer-related acute ischemic stroke

C. Habay, B. Ho-Tin-Noe, I. Arab, L. Kabbaj, M. Mazighi, N. Ajzenberg, J-P. Desilles, D. Faille

- PO-71 Clinical significance of identifying ADAMTS13 and vWF as a high-risk factor for thrombosis in gynecological cancer patients**
V. Bitsadze, A. Vorobev, A. Makatsariya, S. Einullaeva, A. Solopova, J. Khizroeva, A. Shatilina, I. Dikaeva
- PO-72 Platelet proteomic profiling reveals mediators of thrombosis and proteostasis in patients with myeloproliferative neoplasms**
S. Kelliher, S. Gamba, L. Weiss, Z. Shen, M. Marchetti, F. Schieppati, C. Scaife, S. Madden, K. Bennett, A. Fortune, S. Maung, M. Fay, F. Ní Áinle, P. Maguire, A. Falanga, B. Kevane, A. Krishnan
- PO-73 Netosis in gynecological cancer patients during antitumor therapy**
A. Makatsariya, E. Slukhanchuk, V. Bitsadze, A. Solopova, A. Vorobev, J. Khizroeva, N. Makatsariya, M. Kalashnikova, N. Gashimova, M. Kvaratskhelia, S. Einullaeva, I. Dikaeva
- PO-74 Ageing as shared risk factor for cancer and cardiovascular disease: the impact of cancer on vascular remodeling**
E. De Vries, N. Deckers, A. Jaminon, D. Van Der Hove, M. Van Zandvoort, L. Dubois, L. Schurgers

- A**
 Abu Saadeh, F. PO-08
 Adra, N. PO-03
 Afrasiabi, A. PO-27
 Afzal, A. PO-09, PO-10
 Ageno, W. IS, OC-06
 Agnelli, G. IS
 Ahmed, S. PO-28
 Ajayi, I. PO-36
 Ajzenberg, N. PO-70
 Akbari, A. PO-27
 Algaze, S. OC-02
 Alikhan, R. PO-44
 Alonso, B. PO-54, PO-64
 Álvarez Llosa, R.C. PO-31
 Amitrano, M. PO-62
 Andersen, M. PO-14, PO-17
 Angelini, D. PO-38
 Arab, I. PO-70
 Arai, H. OC-02
 Arcega, R. PO-39
 Arfuch, V.M. PO-41, PO-59, PO-60
 Armenian, S. PO-58
 Arraras, J.I. PO-25, PO-43
 Ashouri, K. OC-02
 Asin, G. PO-25
 Aslanova, Z. PO-06, PO-68
 Averya, G. PO-19
 Ávila, I. PO-32
 Ay, C. OC-09, PO-57
 Aznar, M.V. PO-25, PO-43
- B**
 Baddeley, E. PO-41, PO-59, PO-60
 Balas, N. PO-58
 Bander, N.H. PO-03
 Bandyo, R. PO-29
 Barbui, T. PO-02
 Barca-Hernando, M. PL-08, PO-42
 Barcella, L. PO-67
 Barnard, J. PO-66
 Barnum, K. PO-14, PO-17
 Barzegar, H. PO-27
 Battaglin, F. OC-02
 Baxter, K. PO-28
- Becattini, C.** PL-23, OC-06, PO-33
Benito, A. PO-39
Benito, P. PO-54
Bennett, K. PO-72
Berger, J. PO-57
Berghoff, A. OC-09, PO-57
Berry, J. PO-14, PO-17
Bhatia, R. PO-58
Bhatia, S. PO-58
Biesmans, C. PO-04
Biosca Gómez De Tejada, M. PO-12
Bitsadze, V. PO-06, PO-68, PO-71, PO-73
Blake, D. PO-28
Blancarte Ibarra, M. PO-61
Bolognini, S. OC-10, PO-67
Bosch, F.T.M. OC-04
Bosworth, A. PO-58
Bozas, G. PO-19
Braden, V. PO-28
Bramley, M. OC-07, PO-50
Brandão, A.G.S. PO-63
Braun, J. OC-08
Brincat, M. PO-28
Broughton, L. PO-19
Brown, V. PO-19
Brozos Vázquez, E.M. PO-12
Brozos, E. OC-03
Brunetti, N.D. PO-48
Bryan, S. PO-28
Büller, H.R. OC-04
Bundred, N.J. OC-07, PO-50
- C**
 Cacho Lavin, D. PO-24
 Cali, B. PL-13
 Calverley, D.C. PO-65
 Campello, E. OC-04
 Cannavacciuolo, F. PO-62
 Capdevila, J. PO-64
 Carbó Bagué, A. PO-24
 Carmona Bayonas, A. OC-03, PO-12, PO-55
 Carmona Campos, M. OC-03
 Carpenedo, M. PL-11
 Carrier, M. OC-12
 Carson, K. PO-09, PO-10
- Castagna, A.** OC-04
Casteras, A. PO-64
Castle, J. OC-07, PO-50, PO-51
Cazzaniga, M.E. IS
Cedervall, J. PO-56
Chandra, D. OC-11
Chang, S. PO-09, PO-10
Chapelle, C. OC-05, PO-16
Chasakova, K. PO-69
Chatelain, B. PO-53
Chaturvedi, S. PO-38
Cheong, M.A. PO-65
Clarke, R. PO-51
Coll, J. PO-25, PO-43
Collinge, E. PO-15
Colomé, E. PO-39
Coma Salvans, E. PO-24
Coma, E. PO-31, PO-39
Coma-Auli, N. PO-41, PO-59, PO-60
Connors, J.M. OC-12
Constans, J.M. PO-05
Copt, N. PO-40
Cormio, G. PO-48
Covela Rúa, M. OC-03, PO-12
Cox, K. OC-07, PO-50
Cumplido, J.D. PO-24
- D**
 Daddi, A. PO-45
 D'Alessio, A. OC-10
 Damiano, F.P. PO-62
 Davidson, Z. PO-03
 De Braud, F. OC-10
 De La Camara, J. PO-31
 De La Cruz, S. PO-25, PO-43
 De La Haba, I. PO-39
 De La Morena Barrio, M.E. PO-55
 De Laat, B. PO-01, PO-04
 De Luca, R. PO-48
 De Miguel, Y. PO-31
 De Simone, I. PO-04
 De Torner, A. PO-54, PO-64
 De Vos-Geelen, J. PO-01, PO-04
 De Vries, F. PO-74
 Deckers, N. PO-74
 Delluc, A. OC-12

AUTHOR INDEX

Depaus, J. PO-15
Desilles, J-P. PO-70
Di Bona, E. PO-02
Di Nisio, M. PL-18
Díaz Pedroche, C. PO-12, PO-24
Díaz-Montero, M. OC-01
Dikaeva, I. PO-06, PO-71, PO-73
Dilley, J. PO-28
Dinis Santos Rodrigues, C. OC-08
Dobbs, S. PO-28
Dodge, L. PO-14, PO-17
Doherty, D. PO-40
Doux fils, J. OC-06
Dovganych, N. PO-11
Dubois, L. PO-74
Durden, A. PO-28
Dzyuba, M. PO-37

E
Edwards, M. PO-41, PO-59, PO-60
Efendieva, E. PO-06
Einullaeva, S. PO-71, PO-73
Elalamy, I. PO-06, PO-68
Enggaard, H. PO-41, PO-59, PO-60
Englisch, C. OC-09, PO-57
Eremiev, S. PO-54, PO-64
Escaleira, R. PO-35
Espín, S. PO-49

F
Faille, D. PO-70
Falanga, A. IS, OC-06, OC-10, PO-02, PO-67, PO-72
Faryal, R. PO-40
Fay, M. PO-72
Feener, E. PO-66
Fergusson, D. OC-12
Fernández Garay, D. PO-24, PO-31
Fernández Montes, A. PO-55
Fernández Pérez, I. OC-03
Fernandez, I. PO-32
Fernandez, M. PO-14, PO-17
Fernando, S. OC-12

Ferrer Pérez, A.I. PO-24, PO-31
Ferrer, A. PO-32
Fiaccadori, A. PO-33
Fiest, K. OC-12
Fioretti, A.M. PO-48
Font, C. PO-32, PO-41, PO-59, PO-60
Forman, S. PO-58
Fortune, A. PO-72
Francisco, L. PO-58
Friso, S. OC-04
Fritzer-Szekeres, M. OC-09
Fuglsang, C.H. PO-20, PO-21

G
Gage, B. PO-10
Galmiche, A. PO-05, PO-53
Gamba, S. OC-10, PO-67, PO-72
Gangaraju, R. PO-58
García Adrián, S. OC-03, PO-12
García De Herreros, M. OC-03
García Escobar, I. OC-03, PO-31
García Verdejo, F.J. PO-24
García, A. PO-64
Garcia, I. PO-32
Garcia-Garcia, V. PO-42
Garrido Fernández, A. PO-24
Garrido Rodríguez, P. PO-55
Gashimova, N. PO-73
Gasparini, G. OC-10
Gavasso, S. OC-04
Giaccherini, C. PO-67
Gilani, S. OC-11
Girard, P. OC-05, PO-16
Giuliani, F. OC-10
Godin, C. PO-53
Goel, G. PO-45
Gomes, N. PO-28
Gomez, E. PO-25, PO-43
Gomez-Rosas, P. OC-10
González Conejero, R. PO-55
Gonzalez Villarroel, P. PO-31
González, I. PO-32
González-Conejero, R. PO-49
Goplen, D. PO-07

Graf, C. PL-06, OC-08
Gramaça, J. PO-35
Green, L. PO-44
Gresele, P. PL-12
Grigoreva, K. PO-68
Gris, J-C. PO-68
Groves, T. PO-44
Grubovik Ratsvorcev, R. PO-18
Guerreiro, I. PO-35
Guffey, D. PO-29
Guillot, M. PO-31
Gutierrez Bernal, A. PO-38

H
Habay, C. PO-70
Hageman, L. PO-58
Haghpahan, S. PO-27
Haque, F. PO-19
Harenberg, J. OC-06
Harvey, J.R. OC-07, PO-50
Hernández, R. PO-55
Hernando, J. PO-54, PO-64
Herre, M. PO-56
Hetjens, S. OC-06
Hisada, Y. OC-01
Hogan, B. OC-07, PO-50
Højen, A.A. PO-41, PO-59, PO-60
Holcombe, C. OC-07, PO-50
Holodinsky, J. OC-12
Horváth-puhó, E. PO-20, PO-21, PO-26
Ho-Tin-Noe, B. PO-70
Hsu, C. PO-14, PO-17
Hund, T.S. PO-46
Hunt, R. OC-07, PO-50
Huskens, D. PO-01, PO-04

I
Ibrahim, E. PO-08
Iglesias, C. OC-03
Iglesias Pérez, C. PO-12
Illarramendi, J. PO-25, PO-43
Illarramendi, J.J. PO-25, PO-43

J
Jackson, R. OC-07, PO-50
Jafari, O. PO-29
Jaminon, A. PO-74

Jara-Palomares, L. OC-05, PO-16, PO-42
Jayachandran, P. OC-02
Jenkins, S. PO-37
Jiménez Fonseca, P. OC-03, PO-12, PO-55
Jiménez, E. PO-31
Johnsen, S.P. PO-22
Johnston, B. PO-28
Jotwani, A. PO-29, PO-34
Jovanova, N. PO-18

K
Kabbaj, L. PO-70
Kalashnikova, M. PO-73
Kalikasingh, K. PO-52
Kannik, K. PO-22
Karimi, M. PO-27
Karthigayan, K. PO-47
Kelliher, S. PO-40
Kelliher, S. PO-72
Kenet, G. PL-24
Kevane, B. PO-40, PO-72
Khan, F. OC-12
Khargie, N. PO-37
Khizroeva, J. PO-06, PO-68, PO-71, PO-73
Khorana, A.A. PL-16, SKML, OC-01, PO-66
Kirwan, C.C. OC-07, PO-50, PO-51
Klok, F.A. PO-4, PO-59, PO-60
Ko, A.K. PO-13
Kokan, J. OC-07, PO-50
Kokka, F. PO-28
Konings, J. PO-01, PO-04
Korsgaard, S. PO-23
Kosamat, A. PO-36
Kozhukhov, S. PO-11
Krishnan, A. PO-72
Kristensen, F. PO-23
Kuderer, N. PL-17, PO-65
Kudryavtseva, E. PO-06, PO-68
Kurtin, C. PO-37
Kvaratskhelia, M. PO-73

L
La Forgia, D. PO-48
Labianca, R. OC-10

AUTHOR INDEX

Lake, L. PO-38
Landier, W. PO-58
Lanting, V. OC-12
Laporte, S. OC-05, PO-16
Lapping, S. PO-52
Larsen, T.B. PO-22
Lauw, M.N. PO-13
Laville, A. PO-05
Lazarchuk, A. PO-68
Le Gal, G. OC-12
Lee, A.Y.Y. SKML, OC-05, PO-16,
Lee, D. PO-66
Leebeek, F.W.G. PO-13
Lennie Wong, F. PO-58
Lenz, H.J. OC-02
Leopizzi, T. PO-48
Li, A. PL-05, PO-29, PO-34, PO-38
Li, Y. PO-52
Liebman, H. OC-02
Lifford, K. PO-41, PO-59, PO-60
Lim, Y.Y. PO-51
Lindman, H. PO-56
Lo, J.H. OC-02
Lobato, B. PO-32
Lobo De Mena, M. PO-12
Lockley, M. PO-28
López Robles, J. OC-03, PO-24
Lopez Ruz, S. PO-42
Lorenzetti, D. OC-12
Louandre, C. PO-53
Lowe Zinola, J. PO-28
Lozano, M.L. PO-49, PO-55
Luo, S. PO-09, PO-10
Lyman, G.H. IS

M
Ma, S. PO-29
Macia Rivas, L. PO-55
Mackman, N. OC-01
Macleod, H. PO-40
Macleod, S. PO-40
Madden, S. PO-72
Madera, A. PO-52
Madsen, S.S. PO-22
Maguire, C.A. PO-56
Maguire, P. PO-40, PO-72

Mahajan, A. PO-38
Mahé, I. OC-05, PO-16, PO-41, PO-59, PO-60
Mahmoud, A. PO-10
Makatsariya, A. PO-06, PO-68, PO-71, PO-73
Makatsariya, N. PO-06, PO-68, PO-73
Malykh-Bakhtina, M. PO-68
Mangiacapra, S. PO-62
Manterola, A. PO-25
Mantha, S. PL-21
Maraveyas A. PO-19
Maraziti, G. PO-33
Marchetti, M. OC-06, OC-10, PO-02, PO-67, PO-72
Mariathan, S. PO-30
Marini, F. OC-08
Markhus, V. PO-07
Marshall, A. OC-07, PO-50
Martin, K. PO-29, PO-34
Martinelli, N. OC-04
Martínez De Castro, E. OC-03, PO-12, PO-31, PO-55
Martínez Martínez, I. PO-55
Martínez, C. PO-49, PO-55
Martinez, E. PO-32
Martínez, I. PO-49
Martinez, J. PO-32
Martínez, P. PO-54, PO-64
Martínez-Calvillo, M. PO-43
Marx, C. OC-12
Mascaró, P. PO-54
Masci, G. OC-10
Mashkova, T. PO-06
Maung, S. PO-72
May, J. PO-38
Mazighi, M. PO-70
Mc Goldrick, C. PO-08
McCormick, A. PO-28
McCrae, K. OC-01, PO-66
Mendes, J. PO-35
Meng, Q. PO-58
Merino, M. PO-39
Meyer, G. OC-05, PO-16
Micallef, J. PO-56
Millstein, J. OC-02
Minarik, J. PO-69
Mirallas, O. PO-54

AUTHOR INDEX

Mirza, S. PO-19
 Miscevic, N. PO-37
 Mittal, P. OC-02
 Moik, F. OC-09, PO-57
 Mompradé Olivé, E. PO-31
 Morales Arteaga, A. PO-61
 Morales Del Burgo, P. PO-55
 Mulder, F.I. OC-04
 Muñoz Martín, A.J., OC-03,
 PO-12, PO-24, PO-31, PO-32
 Mutsaers, P.N.J. PO-13

N

Nagy, D. PO-20, PO-21, PO-26
 Nagy, M. OC-10
 Nanus, D.M. PO-03
 Nayak, L. PO-52
 Neria, F. PO-12
 Ní Áinle, F. PO-40, PO-72
 Nielsen, C.H.F. PO-26
 Nielsen, C. PO-23
 Nielsen, P.B. PO-22
 Nissl, S. PO-56
 Noble, S. SNS, PO-41,
 PO-44, PO-59, PO-60,
 Nopp, S. OC-09
 Norris, L.A. PO-08
 Nott, C. PO-28
 Nunziata, M. PO-62

O

O' Toole, S. PO-08
 O' Rourke, E. PO-40
 O'Sullivan, J.M. PL-01
 Obispo Portero, B. PO-12
 Ogunlayi, H. PO-51
 Okazaki, E. PO-63
 Olabisi, A. PO-36
 Olaitan, A. PO-28
 Oliva, S. PO-48
 Olivares, H. OC-03
 Olsson, A.K. PO-56
 Oreste, D. PO-48
 Ortega Morán, L. OC-03,
 PO-12
 Ortega, L. PO-32
 Osborne, J. PO-03
 Overvad, T.F. PO-22

Owens, G. PO-28
 Oxley, S. PO-28

P

Pabinger, I. D, OC-09, PO-57
 Pachón, V. PO-32
 Palmieri, C. OC-07, PO-50
 Paloma, M.J. PO-25, PO-43
 Palumbo, J. OC-01
 Pampols, M. PO-31
 Pandit, N. PO-46, PO-47
 Pandya, A. PO-28
 Panev, B. PO-18
 Panicot-Dubois, L. PL-15
 Papajik, T. PO-69
 Parand, S. PO-27
 París Bouzas, L. PO-31
 Parks, A. PO-38
 Patel, A. PO-03
 Patell, R. PL-02, PO-14,
 PO-17, PO-38
 Pattini, P. OC-04
 Pease, N. PO-44
 Pelegrin Mateo, F.J. PO-12,
 PO-31
 Peñas-Martínez, J. PO-49,
 PO-55
 Pereira Elorrieta, A. PO-55
 Petkovik, E. PO-18
 Petrelli, F. OC-10
 Phan, L. PO-61
 Pillai, A. PO-19
 Pititto, G.N. PO-33
 Pizzutilo, P. PO-48
 Poenou, G. OC-05, PO-16
 Porta, R. OC-03
 Power, R. PO-40
 Preusser, M. OC-09, PO-57
 Prince, J. PO-28
 Pritchard, S. OC-07, PO-50,
 PO-51
 Prots, D. PO-52

Q

Qi, Z. PO-47
 Quintanar Verduguez, T.
 PO-12

Quintanar, T. OC-03, PO-24,
 PO-32

R

Racine, F. PO-53
 Rak, J. PL-14
 Ramesh, D. PO-08
 Ranjan, M. PO-29, PO-34
 Raskob, G.E. PL-22
 Redondo, M. PO-25, PO-43
 Reinhardt, C. PL-03
 Ricote, G. PO-55
 Roberston, B. PO-38
 Robles Díaz, L. PO-31
 Roca, M. PO-64
 Roca-Herrera, M. PO-54
 Rocha, V. PO-63
 Rochweg, B. OC-12
 Rodríguez Calvillo, M. PO-25
 Roest, M. PO-01, PO-04
 Rojas Hernandez, C. PO-61
 Rosa-Linares, C. PO-42
 Rosenkrantz, O. PO-20, PO-21
 Ross, E. PO-58
 Rossi, E. PL-07
 Rothschild, C. PO-63
 Rousseau, A. OC-04
 Roy, P. G. OC-07, PO-50
 Rubio, J. OC-03, PO-32
 Ruf W. OC-08
 Ruiz, M. PO-32
 Russo, L. OC-10, PO-02, PO-67
 Ryan, N. PO-28, PO-40
 Ryde, J. PO-19

S

Saeed, K. PO-40
 Saidak, Z. PO-05, PO-53
 Salgado, E. PO-25, PO-43
 Salgado, M. PO-31, PO-32
 Salvador Coloma, C. PO-24
 Sánchez Cánovas, M. OC-03,
 PO-12, PO-24
 Sánchez Togneri, L. OC-03
 Sanchez, O. OC-05, PO-16
 Sanfilippo, K. PL-10, PO-09,
 PO-10, PO-65
 Santiago Crespo, J.A. PO-12

Santoro, A. OC-10
 Sarmiento, R. OC-10
 Sastre, J. PO-31
 Saupe, F. PO-56
 Sawant, S. PO-45
 Sayar, Z. PO-30
 Scaife, C. PO-72
 Schaefer, J. PO-38
 Schieppati, F. OC-10, PO-02,
 PO-72
 Schoen, M. PO-09, PO-10
 Schrörs, B. OC-08
 Schubert, S. OC-08
 Schurgers, L. PO-74
 Scicchitano, P. PO-48
 Seladas, M. PO-35
 Selheim, F. PO-07
 Serradell, S. PO-54, PO-64
 Severinsen, M.T. PO-22
 Sevestre, M.A. PO-05
 Shahsavani, A. PO-27
 Sharma, B. OC-01
 Shatilina, A. PO-71
 Shen, Z. PO-72
 Shim, Y. OC-01, PO-66
 Shlush, L.I. PL-20
 Shorova, M. PO-18
 Sideris, M. PO-28
 Siegal, D. PL-04
 Simioni, P. OC-04
 Singh, U. OC-07
 Sive, J. PO-30
 Sivell, S. PO-41, PO-59, PO-60
 Slavik, L. PO-69
 Slukhanchuk, E. PO-68, PO-73
 Søgaard, M. PO-41, PO-59,
 PO-60
 Solopova, A. PO-06, PO-68,
 PO-71, PO-73
 Sonet, A. PO-15
 Soni, S. OC-02
 Soria, J.M. PO-31, PO-32
 Soto, J. PO-32
 Soudet, S. PO-05
 Sørensen, H.T. PO-20,
 PO-21, PO-23, PO-26
 Spizzo, M. OC-04
 Spronk, H.M.H. OC-10

AUTHOR INDEX

Squizzato, A. PO-33
 Stambolieva, D. PO-18
 Stanworth, S.J. PL-10
 Starostka, D. PO-69
 Starzer, A.M. OC-09
 Steiner, D. OC-09
 Stelfox, H. OC-12
 Stenfeldt, L.G. PO-22
 Stephens, A. PO-19
 Stoileva, M. PO-18
 Strippoli, S. PO-48

T

Tagawa, S.T. PO-03
 Taitor, A. PO-30
 Tan, Y. PO-30
 Tan, Y.R. PO-46
 Tanna, S. PO-28
 Tartari, C.J. OC-10, PO-02,
 PO-67
 Tataka, I. PO-38
 Tefera, L. PO-38
 Teigell, J. PO-24
 Teixeira, L. PO-43
 ten Cate, H. OC-10, PO-01,
 PO-04
 Teruel, R. PO-55
 Tetz, G. PO-56
 Tetz, V. PO-56
 Thachil, J. OC-07, PO-50
 Thomas, A. PO-52
 Thomas, C. PO-03
 Thomas, M. PO-28, PO-30
 Ticozzi, C. OC-10, PO-67
 Tocchetti, C.G. PO-48
 Tondini, C. OC-10
 Tong, E. PO-52
 Torres-Gonzalez, L. OC-02
 Tran, A. OC-12
 Tretyakova, M. PO-06, PO-68
 Tritschler, T. OC-12
 Tudela, C. PO-39
 Tufaha, S. PO-04
 Turner, L. OC-07, PO-50

U

Ulehlova, J. PO-69

V

Van Der Hove, D. PO-74
 Van Dreden, P. OC-04
 Van Es, N. OC-04, OC-12
 Van Zandvoort, M. PO-74
 Vassart, J. OC-06
 Vemuri, K. PO-56
 Verzeroli, C. OC-10, PO-67
 Vicente, V. PO-49
 Villaça, P.R. PO-63
 Vinayagam, R. OC-07, PO-50
 Violi, F. OC-06
 Visa, L. PO-55
 Viuff, J. PO-23
 Vlastic, N. PO-57
 Volleamere, A. OC-07, PO-50
 Vorobev, A. PO-06, PO-68,
 PO-71, PO-73

W

Wahballa, S. PO-51
 Wang, T.-F. PO-09
 Ward, M.P. PO-08
 Waters, J. PO-28
 Weisdorf, D. PO-58
 Weiss, C. OC-06, PO-40, PO-72
 Weitz, J. OC-06
 Wells, P. OC-12
 Willems, R.A.L. PO-01, PO-04
 Wong, A. OC-02
 Wunsch, H. OC-12

Y

Yang, Y. OC-02
 Yaringaño, J. PO-54
 Yeo, E. PO-37
 Young, E. PO-61

Z

Zakharia, Y. PO-03
 Zamesa, N. PO-28
 Zaragoza Huesca, D. PO-49,
 PO-55
 Zhang, W. OC-02
 Zhou, E. PO-29
 Zwicker, J. PL-19, PO-14,
 PO-17

LUNCH SYMPOSIUM
(NOT CME ACCREDITED)



LEO Pharma

May 18th, 2024

from 13:30 to 14:30

📍 Aula Castoldi – Ground floor

**The balancing act of anticoagulation along the dynamic
oncology patient journey**

Welcome and introduction

Chair: Anna Falanga (Italy)

2023 guideline updates and how they impact clinical practice

Anna Falanga (Italy)

Bleeding in CAT patients:
what are the risk factors and how can these be managed?

Marc Carrier (Canada)

Frail CAT patients: considerations for anticoagulation

Simon Noble (UK)

The dynamic nature of the oncology patient: a case study review

Ismail Elalamy (France)

Q&A discussion moderated by Anna Falanga

All Faculty

Closing remarks

Anna Falanga (Italy)



GENERAL INFORMATION

Conference venue

The Conference takes place in Bergamo at the Complex of Sant'Agostino, University of Bergamo, Piazzale Sant'Agostino, 2 - Bergamo, Città Alta (Upper Town).

Organizing Secretariat

Servizi C.E.C. Srl
Via Daste e Spalenga 15 – 24125 Bergamo; Italy
e-mail: info@icthic.com

Registration desk

The registration desk is located at the ground floor. It is staffed continuously every day of the conference. The staff is at your disposal for any information.

Phone: +39 366 7541661

On-site registration

Fees for on-site registration, VAT included are:
Delegate € 850,00
Student € 250,00
Accompanying person € 250,00

Computing, printing and xeroxing

Available on request.

Continuing Medical Education (CME)

The 12th International Conference on Thrombosis and Hemostasis Issues in Cancer has been granted for CME accreditation by:



European Board for Accreditation in Hematology (EBAH)

The 12th ICTHIC (ID number 546106) has been reviewed and approved for CME-CPD accreditation by the European Board for Accreditation in Hematology (EBAH). The EBAH has approved this educational activity for a maximum number of **15 CME-CPD credits**. Each participant should only collect credits for time that she/he actually spent in the educational activity.



European Accreditation Council for Continuing Medical Education (EACCME) and Accreditation Council of Oncology in Europe (ACOE)

The 12th International Conference on Thrombosis and Hemostasis Issues in Cancer (ICTHIC), Bergamo, Italy, 17/05/2024-19/05/2024 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) for a maximum of **13 European CME credits** (ECMEC®s). Each medical specialist should claim only those credits that he/she actually spent in the educational activity.

Badges

All the participants are kindly requested to wear the badge throughout the Conference. Only badge holders are admitted to the Scientific sessions, Exhibition, Catering areas.

For the social dinner please bring with you the ticket delivered at registration.

Certificates of attendance

Participants will receive the certificates from Monday 20th via e-mail, after making the request on Sunday 19th.

Oral Communications

Presentation & Discussion

Time at disposal for each Oral Communication is 15 minutes (10 minutes for presentation + 5 minutes for questions/discussion at the end of each speech).

At the end of the presentation, the chairs of the session handle the Q&A /discussion.

Posters

Viewing Time

Posters pdf can be viewed in the Poster Area of ICTHIC website (icthic.com), from Friday 17th to Sunday 19th.

Mandatory attendance

Poster authors are requested to be present at the start and during the entire poster discussion session.

Discussion

There are 8 poster discussion sessions (duration: 1 hour), each guided by a chair and all held on Saturday, May 18th:

Poster session I:

Biomarkers/Hypercoagulability I
Room 7 (floor 1)

Poster session II:

Thrombohemorrhagic complications
Room 6 (floor 1)

Poster session III:

Epidemiology
Room 8 (floor 1)

Poster session IV:

Thromboprophylaxis in cancer
Aula Magna (ground floor)

Poster session V:

Treatment of thrombosis in cancer
Aula Magna (ground floor)

Poster session VI:

Hemostatic proteins and cancer biology
Room 6 (floor 1)

Poster session VII:

Therapeutic challenges
Room 8 (floor 1)

Poster session VIII:

Biomarkers/Hypercoagulability II
Room 7 (floor 1)

Each presenter has 3 minutes to sum up the poster and 2 minutes for the Q&A/discussion with the chair and participants.

The chair of each session handles the questions in each poster session room.

Slide Center

Slide center is located at **Aula Fornasa** (ground floor). All presenters should check in their slides, pen-drive containing a PowerPoint presentation in 16:9, no later than 2 hours prior to the start of their session. Presentation must be Microsoft PowerPoint/Keynote file and PC/MAC compatible.

Language

The official language of the Conference is English. Translations are not provided.

Meals

Coffee/tea breaks and lunches are included in the Conference fee and are served in the Catering Areas.

Exhibition

The exhibition is located in the Minor Cloister and opening times are the same of the Conference.

Social Media

ICTHIC 2024 encourages the use of social media, such as X, Facebook, LinkedIn, Instagram and other social media platforms at the conference as a way to summarize, highlight, promote the presented materials of the conference in general, provided that:

- Copyright law is observed.
- The speaker is referenced and cited appropriately.

Please use the conference hashtag: **#ICTHIC2024**. To get the latest updates throughout the Congress, follow the ICTHIC on icthic.com, on magazine.icthic.com and the correlated social media (@ICTHIC).

Share your experience (@fondazioneartet) on Facebook, Instagram and LinkedIn.



For Accompanying Persons

Friday May 17th

15:00 Meeting point at the conference venue
Walking tour - Hidden gems of Bergamo.
 Bergamo is home to lush gardens, courtyards, cloisters, and masterpieces of the Venetian Renaissance, but most of them are hidden behind the city's palaces, monasteries, and small churches. Behind the scenes with your guide, you will admire flowering pergolas and private courtyards. Let's discover the hidden side of the city in a perfect mix of nature, art and everyday life!

17:30 Return to the conference venue by TukTuk.

Saturday May 18th

9:30 Meeting point at the conference venue
Discovering Bergamo on the notes of Donizetti. A journey through space and time.
 Exceptional opening and guided tour of the Donizetti Theater. The area where the theater stands was presented to the traveler of the time as a collection of wooden shacks in which merchants displayed their wares. In that place of great wealth stood a number of temporary wooden theaters, which were demolished at the end of the season and rebuilt the following season with the same specially preserved material. In 1897, on the centenary of Gaetano Donizetti's birth, the building took on its present appearance, a majestic structure with one of the largest halls in Italy. "Following" the Maestro's notes, accompanied by the guide's narration, effortlessly aboard an electric TukTuk, you will travel through the streets and places of the city that were the

stage of Donizetti's life: from the Theater dedicated to him in the Lower Town, to his birthplace in the medieval Borgo Canale to the magnificent Basilica of Santa Maria Maggiore where he is buried and celebrated by the romantic marble sculpture.

12:00 Exploration of an ancient private tower house in the Upper Town.

The tour will start from the entrance of the tower house on the ground floor and go up the stairs of the sundial tower, thus gradually discovering the evolution of the building over the centuries, but also of the city of Bergamo itself. Then you will enter the top two floors furnished with furniture and furnishings from the various eras that characterized the lives of those who lived there. You will thus arrive at the top of the tower but be careful... without a lift. You will feel like you are reliving the times that once were firsthand, surrounded by family objects and heirlooms, an experience that will make you love our beautiful city and its most secret peculiarities even more.

13:00 Lunch

14:30 Visit to Valverde Castle.

The origins of Valverde Castle date right back to the 10th century. The castle, which is set among the green and rolling hills that frame the Venetian Walls, is considered to be one of the most outstandingly scenic and panoramic spots in the Bergamo area and boasts a splendid view of the Upper City. Its spacious grounds, which feature a wide variety of different plans and trees, includes a section with an Italian-landscaped garden.

17:00 Return to the conference venue


Social Event for Congress Delegates and Accompanying Persons

Saturday May 18th

20.30 Restaurant Il Pianone
Social dinner (extra charge)

The Pianone was built in the second half of the 1600s on the ruins of a medieval fortress, the outermost point of San Vigilio Castle. Nestled in a luxuriant vegetation in Bergamo Upper town, the restaurant is surrounded by flowers and has a fabulous terrace overlooking Bergamo and its valleys.

Platinum



Gold



Bronze



ITALIA
 Diagnostics is in our blood.



